Potential risks and countermeasures of ensidipine in the treatment of AML

Enasidenib, as a targeted drug for relapsed or refractory acute myeloid leukemia (AML) carrying IDH2 mutations, although it brings new treatment hope to these patients, it is also accompanied by some potential risks and side effects. This article will delve into the possible side effects of ensidipine and their corresponding treatment strategies.

Common adverse reactions and treatments

1.During the use of ensidipine, patients may encounter some common adverse reactions. Among them, digestive tract discomfort, such as nausea, vomiting and diarrhea, is the first problem that many patients encounter. In response to these symptoms, patients can try to adjust their eating habits, such as choosing light, easy-to-digest foods and avoiding foods that are too greasy or irritating. At the same time, eating in portions also helps reduce the burden on the digestive tract. If symptoms persist or worsen, appropriate medications can be used for relief under the guidance of a doctor.

2.Fatigue and weakness are also common phenomena during ensidipine treatment. Patients should maintain adequate rest while taking the medication and try to engage in light physical activity to help relieve fatigue. In addition, communicating with the doctor to understand whether the drug dosage needs to be adjusted or replaced is also an important way to solve this problem.

3.Anemia is another side effect to be aware of. Ensidipine may cause a decrease in red blood cells, causing symptoms of anemia. In this regard, patients can improve anemia by increasing foods rich in iron, vitamin B12 and folic acid. If necessary, your doctor may also recommend the use of iron supplements or other blood-replenishing drugs.

Recognition and treatment of serious side effects

1.Ensidipine may also cause some more serious reactions. Cardiovascular toxicities, such as QT interval prolongation and arrhythmias, are issues that require special vigilance. Patients should undergo regular electrocardiogram examinations during medication to detect and deal with these potential risks in a timely manner.

2.Cytokine release syndrome (CRS) is a potentially life-threatening immune reaction. Symptoms include high fever, chills, and low blood pressure. Once these symptoms occur, patients should seek medical treatment immediately and may need to be treated with corticosteroids and other drugs under the guidance of a doctor.

3.Liver damage is also a risk that cannot be ignored during ensidipine treatment. Jaundice, abdominal pain, and loss of appetite may be signs of liver damage. Patients should regularly monitor liver function during medication. Once abnormalities are found, the medication should be discontinued immediately and corresponding treatment should be carried out under the guidance of a doctor.

4.Because ensidipine may suppress immune function, patients may be more susceptible to infection during treatment. Therefore, it is very important to maintain good personal hygiene, avoid close contact with infected people, and receive preventive anti-infective treatment in a timely manner.

Ensidipine, as a targeted treatment drug forAML, although effective, is also accompanied by a series of potential side effects and risks. Patients and doctors need to work closely to monitor and deal with any adverse reactions promptly to ensure the safety and effectiveness of treatment. Through proper dietary modification, adequate rest, and regular medical monitoring, we can better manage these side effects, thereby improving the patient's quality of life and treatment success.